instit.oncol.cluj-napoca- sectia hematologie - 2012

Citozinarabinozid 2 X 200mg/m2, IV, zilele -5,-4,-3,-2
Melfalan 140mg/m2, IV, ziua -1
Autogrefa de celule stem - ziua 0
10. Schema PEP-C (tratament metronomic)
Prednison 20mg/zi, zilnic sau 5 zile/saptamana
Etopozid 50mg/zi, zilnic sau 5 zile/saptamana
Procarbazina 50mg/zi zilnic sau 5 zile/saptamana
Ciclofosfamida 50mg/zi sau 5 zile/sapt
* Este ideal ca schemele de chimioterapie sa fie facute la timp, indiferent de toxicitatea
hematologica. In caz de toxicitate hematologica, este mai bine sa se asigure masuri suportive
(transfuzii, G-CSF, antibiotice) decat sa se amane administrarile de citostatice.
BIBLIOGRAFIE
1. Williams Hematology, 8 th Edition. McGraw Hill, 2010
2. Petrov L, Cucuianu A, Bojan A, Urian L. Hematologie Clinica. Casa Cartii de Stiinta, Cluj-
Napoca, 2009.
3. Societe Francaise d’Hematologie. Referentiel 2009
4. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin’s
lymphoma. Blood 2011; 117: 4208-4217
5. Maucort-Boulch D, Djeridane M, Roy B, Colonna P, Andrieu JM. Predictive and
discriminating three risk group prognostic scoring system for staging Hodgkin lymphoma.
Cancer 2007;109:256-264.
6. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in
early-stage Hodgkin's disease. N Engl J Med 2007;357:1916-27.
7. Behringer K, Diehl V. Twenty-five years clinical trials of the German Hodgkin Study
Group (GHSG). Eur J Haematol 2005:75:21-25. \
8. Engert A, Eichenauer DA, Dreyling M. Hodgkin’s Lymphoma. ESMO clinical
reccomendations for diagnosis and follow-up. Annals of Oncology 2009, 20, Suppl 4, 108-
109
9. NCCN Guidelines Version 2.2012. Hodgkin’s Lymphoma
http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf